Robert Sherman, MD
Urology · Pembroke Pines, FLNPI 1447210810
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in FL, where the typical reported total is $3,881.
Across 58 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$209
- Rochester Medical Corporation$175
- Axonics, Inc.$152
- Procept Biorobotics Corporation$152
- Aytu Biopharma, Inc.$139
- AstraZeneca$93
- plus $437 from 14 others
Across 13 payments — averaging $14,343 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Provepharm Inc.$186K
What the payments were for
- Food & beverage$1,352100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 6 | $209 |
| Rochester Medical Corporation | 7 | $175 |
| Axonics, Inc. | 5 | $152 |
| Procept Biorobotics Corporation | 2 | $152 |
| Aytu Biopharma, Inc. | 14 | $139 |
| AstraZeneca | 4 | $93 |
| Endo Pharmaceuticals Inc. | 3 | $67 |
| Valencia Technologies Corporation | 1 | $59 |
| Laborie Medical Technologies Corp. | 2 | $55 |
| Halozyme Inc | 2 | $45 |
| Clarus Therapeutics Inc. | 3 | $43 |
| Boston Scientific | 1 | $27 |
| Antares Pharma, Inc. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Coloplast | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Photocure Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,357 in reported general payments places this provider in the 25th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrelstarTriptorelin Pamoate | 104 | $257,112 |
| MyrbetriqMirabegron | 160 | $78,669 |
| Testosterone | 35 | $10,026 |
| Bicalutamide | 192 | $6,108 |
| Terazosin Hcl | 334 | $4,261 |
| Potassium Citrate ErPotassium Citrate | 60 | $3,966 |
| Finasteride | 189 | $3,155 |
| Methenamine Hippurate | 86 | $2,872 |
| Trimethoprim | 55 | $2,383 |
| Tamsulosin Hcl | 174 | $2,158 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 16 | $1,284 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 106 | $1,258 |
| NitrofurantoinNitrofurantoin Macrocrystal | 62 | $1,161 |
| Testosterone Cypionate | 17 | $1,115 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 35 | $1,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Verity Pharmaceuticals Inc.Trelstar | $21 | $257,112104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 935 urology providers in Florida.
Other urology in Pembroke Pines
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
- Raymond PakJacksonville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.